Pfizerite comes down with H1N1 flu; FDA highlights new warnings on seizure meds;

> A Pfizer employee in Groton, Conn., has tested positive for H1N1 flu, the company said, and he is recovering at home; several co-workers are also staying home despite the fact that they're not showing symptoms of the novel flu. Report

> FDA approved new labels for epilepsy drugs that include warnings about an increased risk of suicidal thoughts and behaviors. Report

> South African drugmaker Adcock Ingram reiterated its friendly bid for Cipla Medpro South Africa after the latter's drugs supplier objected to the deal. Report

> Dutch vaccine maker Crucell reported a surprise first-quarter profit, its third in a row, on strong sales of pediatric shots; the company, widely viewed as a takeover target, also reiterated its 2009 outlook. Report

> Pfizer sued Sun Pharmaceuticals, Wockhardt and Lupin to prevent the Indian drugmakers from selling copycat versions of its neuropathic pain drug Lyrica. Report

> Solvay Pharmaceuticals nabbed an FDA approval for its Creon treatment for exocrine pancreatic insufficiency. Report

> Georgia has decided to enter into a $6 million settlement with Eli Lilly over the pharmaceutical giant's off-label promotion of the antipsychotic drug Zyprexa. Report

> Baxter International shareholders overwhelmingly defeated a measure asking the company to move away from testing its medical products on animals. Report

> The FDA asked Caraco Pharmaceuticals, the U.S. subsidiary of India's Sun Pharmaceuticals, to withdraw batches of its generic diabetes med Metformin Hydrochloride because of undersized and oversized tablets. Report

> Scottish pharma Prostrakan asked for FDA approval for its Tostran treatment for low testosterone; the product already is sold in Europe. Report

> One of Eli Lilly's most anticipated new products is one step closer to the goal line: Lilly and partner Amylin Pharmaceuticals asked FDA to approve the once-weekly version of their diabetes med Byetta. Report

> The UK's Nycomed, which was recently rumored to be up for sale, says that it expects to land a U.S. partner for its smoker's lung drug--Daxas--by June. The company adds that it is aiming for an IPO. Report

> Seattle-based Calistoga Pharmaceuticals has kept the faith with its Series A investors, bringing them back for a $30 million second round. Report

> India's Jubilant Biosys has struck a new research and development deal with AstraZeneca that could be worth up to $220 million. Report

> Ernst & Young has come out with its annual review of the biotech industry and it reads more like a progress report on a trip through the Valley of Death. The accounting firm concludes that the biotech business model is 'unsustainable' in a crisis like this. Report

> Sanofi-Aventis is converting a factory near Paris into a biotechnology development hub, with its doors wide open to smaller biotech companies looking to partner on projects. Report

> Even as Canada's biotech industry struggles to survive a savage liquidity crisis, the Ontario government has set aside $100 million to fund new gene-related research work. Report

> In a radical departure from traditional research funding standards, the Bill & Melinda Gates Foundation is handing out 81 grants of $100,000 each to researchers who are thinking big about revolutionary new approaches to protecting people from disease. Report

And Finally... The Obama administration is considering an unprecedented fall vaccination campaign that could entail giving Americans three flu shots--one to combat annual seasonal influenza and two targeted at the new swine flu virus spreading across the globe. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.